Serg Technologies Limited

Company description

SERG Technologies develops wearable technology designed to analyse subconscious muscle contractions in order to meet a range of applications, such as smart prosthetics and controlling TVs.

SERG Technologies is an Imperial College deep tech spin-out company, based in London, England. It was incorporated in February 2019 with a mission to revolutionise the way humans interact with technology by re-inventing human to machine interface and develop anthropocentric solutions in the healthcare field that will improve the quality of life for millions of people. The company's shareholders are its Founders: Ravi Vaidyanathan, Samuel Wilson, Alex Lewis and Christos Kapatos, with the venture firm Imperial Innovations maintaining a stake on behalf of Imperial College, and Velocity-Partners VC being the lead-investor of the pre-seed round that was closed in Jan 2020. Two independent Business-Angels are also shareholders. SERG is working closely with NHS hospitals and leading UK private clinics as well as with market-leading companies in the prosthetics and orthotics, medical and homecare fields, creating partnerships, raising awareness and promoting its technology. Our technology was awarded both the "Most Promising Innovation in Robotics" award by the UK Institution of Engineering and Technology (IET) in 2016, as well as the "National Health Service (NHS) Innovation Challenge Award". It has been featured for innovation by BBC and ITV, and the Team has been invited for presentation at 10 Downing Street.

Project impact

Our PD.Ignite platform is the first of its kind to connect stakeholders within one platform whilst providing continuous monitoring for Parkinson's Disease. Using our patented PD.Ignite wearables and dashboard enables remote continuous monitoring of the motor and non-motor Parkinsonian symptoms (tremor, rigidity, slowness of movement, heart rate, sleep etc), generating patient-specific symptom analytics. These analytics support people with Parkinson's in unlocking personalised care, management and treatment optimisation which can improve their quality of life, give greater control and efficiency for healthcare providers. To further support our research, we have acquired a research space that is used as an additional research site and allows our participants to fully immerse themselves in our research and development trials. The following trials are being conducted: Wearable technology to measure movement symptoms in people with PD; Closed-loop rehabilitation for PD and wider neurological disorders; SERG-ONE - An MMG Sensor Platform to optimise therapy for PD; SERG ONE DBS - MMG for precise, DBS parametrisation to treat PD; Closed-Loop Electronic Stimulation for Passive Tremor Suppression.

This is being assessed in clinical trials with a view for full commercialisation at a later stage.

The company cleared pre-seed commercial investment funding in Jan 2020. In Oct 2020 they prototyped a Parkinson's telemedicine system to be used in the homes of patients as a precursor to a large trial. It has been deployed in several homes for telemedicine from Jan 2021- onwards.